Challenges in Management of Pediatric Chronic Myeloid Leukemia (pCML) in the Low-Middle Income Countries (LMICs): Insights from an International CML Foundation (iCMLf) Multi-National Survey.

IF 1.2 4区医学 Q4 HEMATOLOGY

Pediatric Hematology and Oncology Pub Date : 2024-05-01 Epub Date: 2024-01-16 DOI:10.1080/08880018.2023.2301404

Nirmalya Roy Moulik, Arlene Harriss-Buchan, Giuseppe Saglio, Meinolf Suttorp

引用次数: 0

Abstract

Despite being a rare disease, high-income countries (HICs) have formulated guidelines for management of pediatric CML (pCML). We conducted a survey amongst 24 physicians from 22 Low-Middle Income Countries (LMICs) to gather information regarding their practice and experience in treating children with pCML. Rarity of pCML, lack of adequate expertise, and setting-adapted guidelines along with limitations in diagnostic infrastructure as well as challenges in accessing tyrosine kinase inhibitors (TKIs) were identified as major barriers in optimum management of patients. For the first time in literature, our findings provide valuable insights into the multifaceted challenges faced in managing pCML in LMICs.

查看原文本刊更多论文

中低收入国家（LMICs）儿科慢性粒细胞白血病（pCML）管理面临的挑战：国际慢性粒细胞白血病基金会（iCMLf）多国调查的启示。

尽管是一种罕见疾病，但高收入国家（HICs）已制定了儿科慢性骨髓性白血病（pCML）的治疗指南。我们对来自 22 个中低收入国家 (LMIC) 的 24 名医生进行了调查，以收集他们在治疗 pCML 儿童方面的实践和经验。调查发现，pCML 的罕见性、缺乏足够的专业知识、与环境相适应的指南、诊断基础设施的局限性以及在获得酪氨酸激酶抑制剂 (TKI) 方面的挑战是患者最佳治疗的主要障碍。我们的研究结果首次在文献中提供了有价值的见解，使人们了解到在低收入国家管理 pCML 所面临的多方面挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Hematology and Oncology 医学-小儿科

CiteScore

2.60

自引率

5.90%

发文量

审稿时长

6-12 weeks

期刊介绍： PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.